Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials

01 Aug 2021

Duffey M, Blasco B, Burrows JN, Wells TNC, Fidock DA, Leroy D

Trends in Parasitology
PMID: 34001441

Doi: 10.1016/j.pt.2021.04.006

Photo: Jackson_iStock

Strategies to counteract or prevent emerging drug resistance are crucial for the design of next-generation antimalarials. In the past, resistant parasites were generally identified following treatment failures in patients, and compounds would have to be abandoned late in development. An early understanding of how candidate therapeutics lose efficacy as parasites evolve resistance is important to facilitate drug design and improve resistance detection and monitoring up to the postregistration phase. We describe a new strategy to assess resistance to antimalarial compounds as early as possible in preclinical development by leveraging tools to define the Plasmodium falciparum resistome, predict potential resistance risks of clinical failure for candidate therapeutics, and inform decisions to guide antimalarial drug development.

To view the full article please visit Trends in Parasitology website